Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Libby Black

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
BJU International|February 26, 2009
Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trialJack Barkin, Claus G Roehrborn, Paul Siami, et al.
Journal of Perinatology : Official Journal of the California Perinatal Association|August 10, 2019
Risk of hospitalization for common neonatal morbidities in preterm and term infants: assessing the impact of one or more major congenital anomaliesJanet R Hardy, Jeanne M Pimenta, Shibani Pokras, et al.
Prostate Cancer|April 24, 2014
Burden of Illness in Prostate Cancer Patients with a Low-to-Moderate Risk of Progression: A One-Year, Pan-European Observational StudyCesare Selli, Anders Bjartell, Javier Burgos, et al.
The Journal of Sexual Medicine|August 14, 2013
Safety and efficacy of epelsiban in the treatment of men with premature ejaculation: a randomized, double-blind, placebo-controlled, fixed-dose studyRajesh Shinghal, Allison Barnes, Kelly M Mahar, et al.
Lancet (London, England)|January 27, 2012
Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trialNeil E Fleshner, M Scott Lucia, Blair Egerdie, et al.
Urology|July 19, 2011
Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trialClaus G Roehrborn, J Curtis Nickel, Gerald L Andriole, et al.
Urology|June 29, 2010
Comprehensive quality-of-life outcomes in the setting of a multidisciplinary, equal access prostate cancer clinicKevin Rice, Jane Hudak, Kimberly Peay, et al.
The Patient|December 4, 2017
Experience of Symptoms and Disease Impact in Patients with AdenomyosisLinda M Nelsen, William R Lenderking, Robin Pokrzywinski, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
BJU International|February 26, 2009
Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trialJack Barkin, Claus G Roehrborn, Paul Siami, et al.
Journal of Perinatology : Official Journal of the California Perinatal Association|August 10, 2019
Risk of hospitalization for common neonatal morbidities in preterm and term infants: assessing the impact of one or more major congenital anomaliesJanet R Hardy, Jeanne M Pimenta, Shibani Pokras, et al.
Prostate Cancer|April 24, 2014
Burden of Illness in Prostate Cancer Patients with a Low-to-Moderate Risk of Progression: A One-Year, Pan-European Observational StudyCesare Selli, Anders Bjartell, Javier Burgos, et al.
The Journal of Sexual Medicine|August 14, 2013
Safety and efficacy of epelsiban in the treatment of men with premature ejaculation: a randomized, double-blind, placebo-controlled, fixed-dose studyRajesh Shinghal, Allison Barnes, Kelly M Mahar, et al.
Lancet (London, England)|January 27, 2012
Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trialNeil E Fleshner, M Scott Lucia, Blair Egerdie, et al.
Urology|July 19, 2011
Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trialClaus G Roehrborn, J Curtis Nickel, Gerald L Andriole, et al.
Urology|June 29, 2010
Comprehensive quality-of-life outcomes in the setting of a multidisciplinary, equal access prostate cancer clinicKevin Rice, Jane Hudak, Kimberly Peay, et al.
The Patient|December 4, 2017
Experience of Symptoms and Disease Impact in Patients with AdenomyosisLinda M Nelsen, William R Lenderking, Robin Pokrzywinski, et al.
Pageof 2